Pharmacom Biovet Working Capital vs. Current Liabilities
| PHMB Stock | USD 0.0001 0.00 0.00% |
For Pharmacom Biovet profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Pharmacom Biovet to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Pharmacom Biovet utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Pharmacom Biovet's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Pharmacom Biovet over time as well as its relative position and ranking within its peers.
Pharmacom |
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pharmacom Biovet. If investors know Pharmacom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pharmacom Biovet listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Pharmacom Biovet is measured differently than its book value, which is the value of Pharmacom that is recorded on the company's balance sheet. Investors also form their own opinion of Pharmacom Biovet's value that differs from its market value or its book value, called intrinsic value, which is Pharmacom Biovet's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pharmacom Biovet's market value can be influenced by many factors that don't directly affect Pharmacom Biovet's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pharmacom Biovet's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pharmacom Biovet is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pharmacom Biovet's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Pharmacom Biovet Current Liabilities vs. Working Capital Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Pharmacom Biovet's current stock value. Our valuation model uses many indicators to compare Pharmacom Biovet value to that of its competitors to determine the firm's financial worth. Pharmacom Biovet is regarded third in working capital category among its peers. It is regarded second in current liabilities category among its peers . The current year's Total Current Liabilities is expected to grow to about 74.3 K. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Pharmacom Biovet's earnings, one of the primary drivers of an investment's value.Pharmacom Current Liabilities vs. Working Capital
Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
Pharmacom Biovet |
| = | (29 K) |
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Pharmacom Biovet |
| = | 29 K |
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
Pharmacom Biovet Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Pharmacom Biovet, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Pharmacom Biovet will eventually generate negative long term returns. The profitability progress is the general direction of Pharmacom Biovet's change in net profit over the period of time. It can combine multiple indicators of Pharmacom Biovet, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Operating Income | -639.6 K | -671.6 K | |
| Net Loss | -639.6 K | -671.6 K | |
| Income Before Tax | -639.6 K | -671.6 K | |
| Net Loss | -639.6 K | -671.6 K | |
| Net Loss | -639.6 K | -671.6 K | |
| Change To Netincome | 492.9 K | 468.3 K |
Pharmacom Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Pharmacom Biovet. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Pharmacom Biovet position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Pharmacom Biovet's important profitability drivers and their relationship over time.
Use Pharmacom Biovet in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Pharmacom Biovet position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pharmacom Biovet will appreciate offsetting losses from the drop in the long position's value.Pharmacom Biovet Pair Trading
Pharmacom Biovet Pair Trading Analysis
The ability to find closely correlated positions to Pharmacom Biovet could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Pharmacom Biovet when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Pharmacom Biovet - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Pharmacom Biovet to buy it.
The correlation of Pharmacom Biovet is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Pharmacom Biovet moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Pharmacom Biovet moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Pharmacom Biovet can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Pharmacom Biovet position
In addition to having Pharmacom Biovet in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Utilities Thematic Idea Now
Utilities
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Utilities theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Utilities Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Your Equity Center. For information on how to trade Pharmacom Stock refer to our How to Trade Pharmacom Stock guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
To fully project Pharmacom Biovet's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Pharmacom Biovet at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Pharmacom Biovet's income statement, its balance sheet, and the statement of cash flows.